Results 1 to 10 of about 50,358 (293)

Therapeutic advances in leiomyosarcoma

Frontiers in Oncology, 2023
Leiomyosarcoma is an aggressive mesenchymal malignancy and represents one of the most common subtypes of soft tissue sarcomas. It is characterized by significant disease heterogeneity with variable sites of origin and diverse genomic profiles.
Kristine Lacuna, Sminu Bose, Matthew Ingham, Gary Schwartz   +3 more
doaj   +2 more sources

Cutaneous leiomyosarcoma: a 20-year retrospective study and review of the literature

Anais Brasileiros de Dermatologia, 2021
Background: Cutaneous leiomyosarcoma is a rare malignant neoplasm with muscular origin, representing 2%-3% of all cutaneous soft tissue sarcomas. Objectives: The aim of this study was to characterize clinicopathological features of patients diagnosed ...
Catarina Soares Queirós, Paulo Filipe, Luís Soares de Almeida   +2 more
doaj   +2 more sources

Prostate leiomyosarcoma treatment using three-dimensional reconstruction: a case report and literature review [PDF]

Journal of Men's Health, 2021
Background: Prostate sarcoma is a malignant tumor from the prostate stroma. However, its pathogenesis is unknown. This is a rare type of prostate tumor. Case Presentation: A rare case of prostate leiomyosarcoma has been described.
Zhu-Nan Xu, Tong Cai, Zhong-Bao Zhou, Ji-Tao Wu, Zhen-Li Gao   +4 more
doaj   +1 more source

Targeting the Molecular and Immunologic Features of Leiomyosarcoma

Cancers, 2023
Simple Summary Immunotherapy has revolutionized cancer care across different cancer types. Unfortunately, leiomyosarcoma does not seem sensitive to the first-generation immune-based therapies.
B. Cope, R. Traweek, R. Lazcano, E. Keung, A. Lazar, C. Roland, E. Nassif   +6 more
semanticscholar   +1 more source

Aberrant Activation of Cell-Cycle–Related Kinases and the Potential Therapeutic Impact of PLK1 or CHEK1 Inhibition in Uterine Leiomyosarcoma

Clinical Cancer Research, 2022
Purpose: Uterine leiomyosarcoma is among the most aggressive gynecological malignancies. No effective treatment strategies have been established. This study aimed to identify novel therapeutic targets for uterine leiomyosarcoma based on transcriptome ...
Kosuke Yoshida, Akira Yokoi, Tomofumi Yamamoto, Yusuke Hayashi, J. Nakayama, Tsuyoshi Yokoi, Hiroshi Yoshida, Tomoyasu Kato, H. Kajiyama, Yusuke Yamamoto   +9 more
semanticscholar   +1 more source

A differential diagnosis between uterine leiomyoma and leiomyosarcoma using transcriptome analysis

BMC Cancer, 2023
Background The objective of this study was to estimate the accuracy of transcriptome-based classifier in differential diagnosis of uterine leiomyoma and leiomyosarcoma.
Kidong Kim, Sarah Kim, TaeJin Ahn, Hyojin Kim, So-Jin Shin, Chel Hun Choi, Sungmin Park, Yong-Beom Kim, Jae Hong No, Dong Hoon Suh   +9 more
doaj   +1 more source

Integrative Genomic and Transcriptomic Profiling Reveals a Differential Molecular Signature in Uterine Leiomyoma versus Leiomyosarcoma

International Journal of Molecular Sciences, 2022
The absence of standardized molecular profiling to differentiate uterine leiomyosarcomas versus leiomyomas represents a current diagnostic challenge. In this study, we aimed to search for a differential molecular signature for these myometrial tumors ...
A. Machado-Lopez, R. Alonso, V. Lago, J. Jimenez-Almazan, M. García, J. Monleón, S. López, F. Barceló, A. Torroba, S. Ortiz, S. Domingo, C. Simòn, A. Mas   +12 more
semanticscholar   +1 more source

Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first‐line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

Cancer, 2020
The optimal treatment for advanced leiomyosarcoma is still debated. Given histotype‐specific prospective controlled data lacking, this study retrospectively evaluated doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, and doxorubicin alone as ...
L. D’Ambrosio, Nathan Touati, J. Blay, G. Grignani, R. Flippot, A. Czarnecka, S. Piperno-Neumann, J. Martín-Broto, R. Sanfilippo, D. Katz, F. Duffaud, B. Vincenzi, D. Stark, F. Mazzeo, Armin Tuchscherer, C. Chevreau, J. Sherriff, A. Estival, S. Litière, W. Sents, I. Ray-Coquard, F. Tolomeo, A. Le Cesne, P. Rutkowski, S. Stacchiotti, B. Kasper, H. Gelderblom, A. Gronchi   +27 more
semanticscholar   +1 more source

Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival

Nature Communications, 2021
Leiomyosarcomas (LMS) are genetically heterogeneous tumors differentiating along smooth muscle lines. Currently, LMS treatment is not informed by molecular subtyping and is associated with highly variable survival. While disease site continues to dictate
Nathaniel D. Anderson, Y. Babichev, F. Fuligni, Federico Comitani, M. Layeghifard, Rosemarie E. Venier, S. Dentro, Anant Maheshwari, S. Guram, C. Wunker, J. D. Thompson, K. Yuki, Huayun Hou, M. Zatzman, Nicholas Light, M. Bernardini, J. Wunder, I. Andrulis, P. Ferguson, A. Razak, C. Swallow, J. Dowling, R. Al-Awar, R. Marcellus, M. Rouzbahman, M. Gerstung, D. Durocher, Ludmil B. Alexandrov, B. Dickson, R. Gladdy, A. Shlien   +30 more
semanticscholar   +1 more source

Imaging Findings of Primary Adrenal Leiomyosarcoma: A Case Report

대한영상의학회지, 2020
Leiomyosarcoma is a malignant tumor that typically originates from either the uterus or the retroperitoneum. Furthermore, primary adrenal leiomyosarcoma is an extremely rare condition.
Hye Ran Yoon, Dong Hee Park
doaj   +1 more source